Synergistic Effects of Resistin and Visfatin as Adipocyte Derived Hormones on Telomerase Gene Expression in AGS Gastric Cancer Cell Line
,
Abstract
Recently suggested that adipocytokines may play a role in pathogenesis and progression of certain cancers, especially in gastric cancer. The previous study showed Resistin and Visfatin, as adipocyte derived hormones, separately increases telomerase (hTERT) gene, the aim of this study is investigating synergic effects of Resistin and Visfatin on telomerase gene expression, in AGS gastric cancer cell line. In this study, human gastric cancer AGS cell line was selected. After stimulation with increasing concentrations of Resistin and Visfatin recombinant proteins for 24 and 48 hours, cell proliferation was assessed by XTT assay. In order to investigate the telomerase gene expression affected by these proteins, total RNA was extracted, cDNA was synthesized, and expression of hTERT mRNA was carried out by real-time reverse transcription polymerase chain reaction. After Resistin and Visfatin, recombinant proteins treatment was increased the gastric cell line proliferation and expression of Human Telomerase Reverse Transcriptase (hTERT), but co-stimulation with Resistin and Visfatin showed greater inducible effects on cell proliferation and telomerase gene expression in comparison with the stimulatory effect of the individual hormone. This study has shown Resistin, and Visfatin synergistically increased gastric cancer cell proliferation and enhanced the telomerase gene expression. These data showed that these two hormones in gastric cancer tissue could cooperatively accelerate cancer cell growth via enhancing the telomerase expression as a cancer gene.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
Parkin DM, International variation. Oncogene 2004;23:6329-40.
Guilford P, Hopkins J, Harraway J, Mcleod M, Mcleod N, Harawira P, et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998;392:402-5.
Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;2:58-60.
Malekzadeh R, Derakhshan MH, Malekzadeh Z. Gastric cancer in Iran: epidemiology and risk factors. Arch Iran Med 2009;12:576-83.
Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol 2002;3:565-74.
Calle EE, Kaaks R, Overweight, obesity and cancer:epidemiological evidence and proposed mechanisms. Nat Rev Cancer 004;4:579-91.
Gunter MJ,Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem 2006;17:145-56.
Karastergiou K, Mohamed-Ali V. The autocrine and paracrine roles of adipokines. Mol Cell Endocrinol 318:69-78.
Al-Harithy RN, Al-Ghafari AB. Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J 2010;31:495-500.
Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H, et al. Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 2009;44:685-90.
.Lin NF, Tang J, Ismael HS. Study on environmental etiology of high incidence areas of liver cancer in China. World J Gastroenterol 2000;6:572-6.
.Tuo BG, Yan YH, Ge ZL, Ou GW, Zhao K. Ascorbic acid secretion in the human stomach and the effect of gastrin. World J Gastroenterol 2000;6:704-8.
Wu YA, Lu B, Liu J, Li J, Chen JR,Hu SX. Consequence alimentary reconstruction in nutritional status after total gastrectomy for gastric cancer. World J Gastroenterol 1999;5:34-7.
Zhang XY. Some recent works on diagnosis and treatment of gastric cancer. World J Gastroenterol 1999;5:1-3.
Zhou HP, Wang X, Zhang NZ. Early apoptosis in intestinal and diffuse gastric carcinomas. World J Gastroenterol 2000;6:898-901.
Zou SC, Qiu HS, Zhang CW,Tao HQ. A clinical and long-
term follow-up study of peri-operative sequential triple therapy for gastric cancer. World J Gastroenterol 2000;6:284-6.
Maruyama Y, Hanai H, Fujita M, Kaneko E. Telomere length and telomerase activity in carcinogenesis of the stomach. Jpn J Clin Oncol 1997;27:216-20.
Tahara H, Kuniyasu H, Yokozaki H, Yasui W, Shay JW, Ide T, et al. Telomerase activity in preneoplastic and neoplastic gastric and colorectal lesions. Clin Cancer Res 1995;1:1245-51.
Kuniyasu H, Domen T, Hamamoto T, Yokozaki H, Yasui W, Tahara H, et al. Expression of human telomerase RNA is an early event of stomach carcinogenesis. Jpn J Cancer Res 1997;88:103-7.
Kaszubowska L. Telomere shortening and ageing of the immune system. J Physiol Pharmacol 2008;59:169-86.
Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia 2000;2:426-32.
Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia 2000;2:433-40.
Trayhurn P,Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-39.
Wozniak SE, Gee LL, Wachtel MS, Frezza EE. Adipose tissue: the new endocrine organ? A review article. Dig Dis Sci 2009;54:1847-56.
Mohammadi M ZN, Hedayati M, Ghaemmaghami S. Resistin Effects on Telomerase Gene Expression in AGS Gastric Cancer Cell line. Acta Endocrinol 2016;12:145-9.
Bokarewa M, Nagaev I, Dahlberg L, Smith U,Tarkowski A, Resistin. an adipokine with potent proinflammatory properties. J Immunol 2005;174:5789-95.
Mohammadi M, Zarghami N, Hedayati M, Ghaemmaghami S, Yamchi RM, Mohaddes M. Visfatin effects on telomerase gene expression in AGS gastric cancer cell line. Indian J Cancer 2015;52:32-5.
Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 2004;110:3335-40.
Kolosova IA, Angelini D, Fan C, Skinner J, Cheadle C, Johns RA. Resistin-like molecule alpha stimulates proliferation of mesenchymal stem cells while maintaining their multipotency. Stem Cells Dev 2013;22:239-47.
Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES, et al. Expression of resistin in the prostate and itsstimulatory effect on prostate cancer cell proliferation. BJU Int 108:E77-83.
Zheng LD, Tong QS, Weng MX, He J, Lv Q, Pu JR, et al. Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci 2009;54:274-81.
Hufton SE, Moerkerk PT, Brandwijk R, De Bruine AP, Arends JW, Hoogenboom HR. A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization. FEBS Lett 1999;463:77-82.
Lee YC, Yang YH, Su JH, Chang HL, Hou MF,Yuan SS. High visfatin expression in breast cancer tissue is associated with poor survival. Cancer Epidemiol Biomarkers Prev 2011;20:1892-901.
Shackelford RE, Bui MM, Coppola D,Hakam A. Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol 2010;3:522-7.
Yang Y, Zhou L, Lu L, Wang L, Li X, Jiang P, et al. A novel miR-193a-5p-YY1-APC regulatory axis in human endometrioid endometrial adenocarcinoma. Oncogene 2013;32:3432-42.
Wang B, Hasan MK, Alvarado E, Yuan H, Wu H,Chen WY. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2010;30:907-21.
Patel ST, Mistry T, Brown JE, Digby JE, Adya R, Desai KM, et al. A novel role for the adipokine visfatin/pre-B cell colony-enhancing factor 1 in prostate carcinogenesis. Peptides 2010;31:51-7.
Bae SK, Kim SR, Kim JG, Kim JY, Koo TH, Jang HO, et al. Hypoxic induction of human visfatin gene is directly mediated by hypoxia-inducible factor-1. FEBS Lett 2006;580:4105-13.
Kim JG, Kim EO, Jeong BR, Min YJ, Park JW, Kim ES, et al. Visfatin stimulates proliferation of MCF-7 human breast cancer cells. Mol Cells 2010;30:341-5.
Wang P, Xu TY, Guan YF, Su DF, Fan GR,Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide
mononucleotide. Cardiovasc Res 2009;81:370-80.
Zhang LY, Liu LY, Qie LL, Ling KN, Xu LH, Wang F, et al. Anti-proliferation effect of APO866 on C6 glioblastoma cells by inhibiting nicotinamide phosphoribosyltransferase. Eur J Pharmacol 2012;674:163-70.
Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, et al. Telomerase activity in gastric cancer. Cancer Res 1995;55:3258-62.
Jong HS, Park YI, Kim S, Sohn JH, Kang SH, Song SH, et al. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer 1999;86:559-65.
Shen ZY, Xu LY, Li EM, Cai WJ, Chen MH, Shen J, et al. Telomere and telomerase in the initial stage of immortalization of esophageal epithelial cell. World J Gastroenterol 2002;8:357-62.
Yao XX, Yin L, Sun ZC, The expression of hTERT mRNA and cellular immunity in gastric cancer and precancerosis. World J Gastroenterol 2002;8:586-90.
Holt SE, Shay JW, Wright WE. Refining the telomere-telomerase hypothesis of aging and cancer. Nat Biotechnol 1996;14:836-9.
Hoos A, Hepp HH, Kaul S, Ahlert T, Bastert G,Wallwiener D. Telomerase activity correlates with tumor aggressiveness and reflects therapy effect in breast cancer. Int J Cancer 1998;79:8-12.
Kyo S, Takakura M, Tanaka M, Kanaya T, Sagawa T, Kohama T, et al. Expression of telomerase activity in human chorion. Biochem Biophys Res Commun 1997;241:498-503.
Takakura M, Kyo S, Kanaya T, Tanaka M, Inoue M. Expression of human telomerase subunits and correlation with telomerase activity in cervical cancer. Cancer Res 1998;58:1558-61.
Shay JW, Gazdar AF. Telomerase in the early detection of cancer. J Clin Pathol 1997;50:106-9.
Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 2008;27:3754-60.
| Files | ||
| Issue | Vol 55, No 10 (2017) | |
| Section | Original Article(s) | |
| Keywords | ||
| Visfatin Resistin Gastric cancer AGS cell line | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
